

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address:

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/076,115 05/12/98 GRUBER C 0942.4350001 **EXAMINER** HM12/0523 BRIAN J DEL BUONO TUNG, J STERNE KESSLER GOLDSTEIN AND FOX **ART UNIT** PAPER NUMBER SUITE 600 21 1100 NEW YORK AVENUE NW 1656 WASHINGTON DC 20005-3934 **DATE MAILED:** 05/23/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Application No.

Office Action Summary

09/076,115

Joyce Tung

Applicant(s)

Examiner

Art Unit **1656**

Gruber et al



The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE 3 MONTH(S) FROM
 Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, be considered timely. If NO period for reply is specified above, the maximum statutory period. 	ation.
communication. - Failure to reply within the set or extended period for reply will, by - Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	statute, cause the application to become ABANDONED (35 U.S.C. § 133). mailing date of this communication, even if timely filed, may reduce any
Status	
1) X Responsive to communication(s) filed on 3/12/01	··
2a) ☑ This action is FINAL . 2b) ☐ This act	ion is non-final.
3) Since this application is in condition for allowance e closed in accordance with the practice under Ex pair	
Disposition of Claims	
4) 🔀 Claim(s) 1, 2, 6, 12, 16-20, 22, 25, 28, 29, 31, ar	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideration.
5) Claim(s)	is/are allowed.
6) 💢 Claim(s) <u>1, 2, 6, 12, 16-20, 22, 25, 28, 29, 31, ar</u>	od 32 is/are rejected.
7) Claim(s)	<u>-</u>
	are subject to restriction and/or election requirement.
Application Papers	
9) The specification is objected to by the Examiner.	
10) The drawing(s) filed on is/are	objected to by the Examiner.
11) The proposed drawing correction filed on	•
12) The oath or declaration is objected to by the Exami	
Priority under 35 U.S.C. § 119	
13) ☐ Acknowledgement is made of a claim for foreign per a) ☐ All b) ☐ Some* c) ☐ None of:	riority under 35 U.S.C. § 119(a)-(d).
1. Certified copies of the priority documents hav	e been received.
2. Certified copies of the priority documents hav	•
3. Copies of the certified copies of the priority d application from the International Bure	au (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of th	
14) Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. & F15(e).
Attachment(s)	
15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) X Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20	20) Other:

Application/Control Number: 09/076,115

Art Unit: 1656

Response to Amendment

- 1. The amendment file 3/12/2001 has been entered.
- 2. The rejection of claims 41-43 under 35 U.S.C. §102(e) is withdrawn because of the amendment.
- 3. The rejection of claims 6, 20 and 32 under 35 U.S.C. §112, second paragraph is with drawn because of the amendment.
- 4. Regarding the rejection of claims 1,2, 6, 12, 16-20, 22, 25, 28, 29, 31 and 32 under 35

 U.S.C. §103(a) over Burmer in view of Carninci et al., the response argues that Burmer does not disclose using primer-adapter molecules to produce a product nucleic acid molecule. Burmer dose disclose that the method involves using an adaptor which includes a restriction site and a ligand binding end ligated to the nucleic acid fragment of a first and second nucleic acid samples to provide the nucleic acid complementary to a primer for amplification (see column 4, lines 16-25). This suggests that the primer comprises the nucleic acid sequence which is complementary to the adaptor which includes a restriction site and a ligand binding end. The isolation step is done by first removing the adaptors by restriction enzyme, capturing the nucleic acid containing the ligand and then the nucleic acid that were not captured is isolated (see column 2, lines 56-59). Thus, one of skill in the art at the time of the instant invention would have been motivated to design the primer-adapter as claimed to make the instant invention.

Application/Control Number: 09/076,115 Page 3

Art Unit: 1656

The response further argues that the deficiencies of Burmer are not cured by the disclosure of Carninci in which Carninci et al. do not suggest using primer containing both cleavage sites and ligands. Carninci et al. disclose that the method involves using a primer inserted with restriction sites, the restriction sites are incorporated into cDNA by PCR with ExTaq DNA polymerase and the amplified nucleic acid is cleaved by the restriction enzyme (see pg. 329, column 1-2, the fourth and fifth paragraph). Thus, one of skill in the art at the time of the instant invention would have been motivated to combine the teachings of Burmer and Carninci et al. to design the primer-adapter as claimed to make the instant invention. Therefore, the rejection is maintained.

- 5. Claims 1, 2, 6, 12, 16-20, 22, 25, 28, 29, and 31-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Burmer (5,726,022) in view of Carninci et al. (Genomics, 1996, Vol. 37, pg. 327-336).
- 6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 09/076,115

Art Unit: 1656

however, will the statutory period for reply expire later than SIX MONTHS from the mailing date

Page 4

of this final action.

7. Any inquiries concerning this communication or earlier communications from the examiner

should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can

normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Gary Jones can be reached at (703) 308-1152.

Any inquiries of a general nature or relating to the status of this application should be

directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

8. Papers related to this application may be submitted to Group 1600 by facsimile

transmission. Papers should be faxed to Art Unit 1656 via the PTO Fax Center located in Crystal

Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the

notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

May 11, 2001

EGGERTON A. CAMPBELL
PRIMARY EXAMINER